Legal & General Group Plc Has $922,000 Holdings in Anika Therapeutics Inc (ANIK)

Legal & General Group Plc raised its stake in Anika Therapeutics Inc (NASDAQ:ANIK) by 6.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,039 shares of the biotechnology company’s stock after purchasing an additional 1,762 shares during the period. Legal & General Group Plc owned about 0.20% of Anika Therapeutics worth $922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. BlackRock Inc. raised its position in Anika Therapeutics by 7.7% in the 2nd quarter. BlackRock Inc. now owns 2,057,830 shares of the biotechnology company’s stock valued at $65,851,000 after purchasing an additional 147,627 shares in the last quarter. Spark Investment Management LLC increased its holdings in shares of Anika Therapeutics by 34.6% in the 2nd quarter. Spark Investment Management LLC now owns 21,800 shares of the biotechnology company’s stock valued at $697,000 after acquiring an additional 5,600 shares during the last quarter. FDx Advisors Inc. increased its holdings in shares of Anika Therapeutics by 18.0% in the 2nd quarter. FDx Advisors Inc. now owns 8,205 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 1,253 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Anika Therapeutics by 202.5% in the 2nd quarter. American Century Companies Inc. now owns 15,039 shares of the biotechnology company’s stock valued at $481,000 after acquiring an additional 10,068 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Anika Therapeutics by 3.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 78,929 shares of the biotechnology company’s stock valued at $2,526,000 after acquiring an additional 2,544 shares during the last quarter. 95.05% of the stock is currently owned by institutional investors.

A number of research analysts have recently commented on the company. Barrington Research downgraded Anika Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 20th. First Analysis downgraded Anika Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $45.00 to $34.00 in a report on Wednesday, June 20th. BidaskClub upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 16th. Zacks Investment Research downgraded Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 17th. Finally, ValuEngine upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 3rd. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $43.00.

ANIK opened at $43.00 on Tuesday. Anika Therapeutics Inc has a one year low of $28.54 and a one year high of $69.81. The stock has a market capitalization of $615.14 million, a PE ratio of 21.94, a price-to-earnings-growth ratio of 2.72 and a beta of 2.04.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, July 25th. The biotechnology company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.39. Anika Therapeutics had a return on equity of 9.53% and a net margin of 16.94%. The business had revenue of $30.55 million for the quarter, compared to the consensus estimate of $27.47 million. During the same quarter in the prior year, the business posted $0.76 EPS. The business’s revenue for the quarter was down 8.7% on a year-over-year basis. As a group, sell-side analysts forecast that Anika Therapeutics Inc will post 1.55 earnings per share for the current year.

About Anika Therapeutics

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Read More: How is a Moving Average Calculated?

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply